New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
about
Pharmacogenetic studies update in type 2 diabetes mellitusModulation of Pantothenate Kinase 3 Activity by Small Molecules that Interact with the Substrate/Allosteric Regulatory DomainIntense management of diabetes mellitus: role of glucose control and antiplatelet agentsRosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese ratsThe management of type 2 diabetic patients with hypoglycaemic agentsMolecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist.Therapeutic Implications of PPARgamma in Human Osteosarcoma.Molecular mechanism of insulin resistance in obesity and type 2 diabetes.Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscleProtein tyrosine phosphatase 1B inhibitors: a molecular level legitimate approach for the management of diabetes mellitus.Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases.Thiazolidinedione-induced edema.The clinical biochemistry of obesity.Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders.Do PPARgamma Ligands Suppress the Growth of Cholangiocarcinoma or the Cholangiohepatitis Induced by the Tumor?Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.Pharmacogenetics of glucose-lowering drug treatment: a systematic review.The prince and the pauper. A tale of anticancer targeted agents.Labisia pumila Upregulates Peroxisome Proliferator-Activated Receptor Gamma Expression in Rat Adipose Tissues and 3T3-L1 Adipocytes.Short insulin tolerance test can determine the effects of thiazolidinediones treatment in type 2 diabetesThe possible role of peroxisome proliferator-activated receptor gamma in heart failure.A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeInPeroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes.Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies.PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011 - 2014).Establishment of a cell-based drug screening model for identifying agonists of human peroxisome proliferator-activated receptor gamma (PPARγ).A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells.FGT-1 is the major glucose transporter in C. elegans and is central to aging pathways.Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.Identification of novel metabolites of pioglitazone in rat and dog.Antihyperglycemic effect of carvacrol in combination with rosiglitazone in high-fat diet-induced type 2 diabetic C57BL/6J mice.Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation.Murine model and mechanisms of treatment-induced painful diabetic neuropathy.Systemic analysis of gene expression profiles in porcine granulosa cells during aging.Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes.Thiazolidinediones improve beta-cell function in type 2 diabetic patients.Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?
P2860
Q26739350-E1DB9979-4068-4CBC-9E5F-728A498F2FF1Q27664193-251B2868-94E8-4638-981F-9A67D64A3B79Q28168035-E0FABCCF-A874-4175-B3C8-00819B387CB6Q28567576-CF5C75FE-FCEF-4BDC-819D-DFAA0B890D8FQ30417363-EECB5E4E-294B-4A5D-B84C-1E607FD3E872Q30888347-022A5EBE-08E3-46C2-A6FF-B85411EA4F08Q33674615-BBE8C7EF-1EEB-40AD-BDFD-86ECBAB4A8D4Q33893897-033DF374-F576-444A-9050-A3BB84EB2AE9Q34002703-D57C41EC-AC5B-4604-A11B-93668C115823Q34135843-0774EE80-506A-4D03-8B1C-FADA116FE43FQ34580424-8A3110CD-4B8D-41CC-BAE6-F8E163BC6A64Q34748861-6ABA7533-90EA-4161-B4F6-33E41A0885B8Q35819237-4497F9A4-E5FB-4F97-B15D-160057D8490DQ36724770-F9D23116-3FC0-4D4B-A0E7-D0DF1DC28560Q36743971-73A3D0F8-07C4-46AF-A610-521758C80716Q36892807-F9A60204-9004-45DA-BC08-FA9DC75DA4FCQ36982648-5A62FF6E-D586-4759-9DB1-D2F0F0E98B66Q37042365-AF775F28-C281-4BB4-9B69-2750A2D8161BQ37044454-2B2F213D-545F-46A4-9A20-05A867797860Q37065234-AE40EF8E-47A5-48D1-912A-DB3883B9DC2BQ37277818-5AC797F1-72AC-4BC3-8CE9-AC5630A2CAC9Q37429296-6C20EBB3-619A-4F22-9E3F-D0DEEC192928Q37992593-067BAD1C-3654-49D7-8850-B96B1C7F9360Q38017727-F3ABF9B6-8C65-4F84-AB23-3B5DDFFA584FQ38239632-2F604EAB-5D63-4CED-BA27-D5F3199AF593Q39370163-3AFE207B-78FC-4326-849C-895015B99BCEQ40657052-C177FF90-86DA-4317-B410-363DA5E38507Q41883800-BB1A196B-5B85-4B49-A68C-5573022AB2C9Q42439893-768FE4D8-76E5-4A76-9927-FCE072AA74F3Q44303781-9B015988-F041-4A2A-8FBF-D95D834E2720Q44440351-CA093201-9DBE-4825-AEAC-BC46DFF866BBQ44800245-06C51E86-D82A-4971-9FA4-501307F5B0AAQ44818615-F0C75AB8-BAE8-4650-99A7-88C452B8153EQ46386644-B3BE8899-9E38-4045-8A84-31F349D28C21Q46418736-9B99FDA2-4DD8-4FCB-80AF-277F6DF56C50Q47120023-18A7F6BE-E0CB-45ED-858F-83A7E0E9C398Q48457425-413A0F02-DD6D-4E36-A021-C175B94B5CE7Q51485541-37D71328-6E4A-4716-BEB6-62B6811A011FQ55397745-44A62D94-AFE2-4B0B-9879-C37C3FAEF164
P2860
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
@ast
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
@en
type
label
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
@ast
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
@en
prefLabel
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
@ast
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
@en
P1476
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
@en
P2093
P304
P356
10.1146/ANNUREV.MED.52.1.239
P577
2001-01-01T00:00:00Z